poisar

Stocks · News reference

Summit Therapeutics Awaits FDA Decision on Ivonescimab for Lung Cancer

Fiscal.ai

Summit Therapeutics is awaiting a critical FDA decision regarding its investigational cancer drug, ivonescimab, for the treatment of advanced non-small cell lung cancer.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading